Ginkgo Bioworks Holdings, Inc. (DNA) Registers a Bigger Fall Than the Market: Important Facts to Note

Group 1 - Ginkgo Bioworks Holdings, Inc. closed at $15.24, down 5.28% from the previous trading session, which is less than the S&P 500's loss of 0.28% [1] - Prior to the recent trading day, the company's shares had increased by 56.37%, significantly outperforming the Medical sector's gain of 3.31% and the S&P 500's gain of 4.03% [1] Group 2 - The upcoming earnings release is projected to show an EPS of -$1.24, reflecting a 14.81% decrease compared to the same quarter last year, with expected revenue of $39 million, down 56.2% from the prior-year quarter [2] - For the entire fiscal year, the Zacks Consensus Estimates predict an EPS of -$5.27 and revenue of $181 million, indicating changes of +49.13% and -20.28% respectively from the previous year [3] Group 3 - Recent revisions to analyst forecasts for Ginkgo Bioworks are important as they indicate changing near-term business trends, with upward revisions suggesting analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a history of outperforming, with 1 stocks returning an average annual gain of +25% since 1988; Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold) [6] Group 4 - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries, indicating strong performance potential [7]